Microbiome and Proteome Mapping in Periodontitis
Saliva Versus All-Site Microbiome and Proteome Mapping in Periodontitis
1 other identifier
observational
3
1 country
1
Brief Summary
This study aimed to compare the microbiome and proteome profiles of saliva, serum and all periodontal sites in patients with periodontitis. Saliva, serum, gingival crevicular fluid and subgingival plaque were obtained from three patients with stage III, grade C periodontitis. Quantitative proteomics were performed for proteome analysis of saliva, serum and gingival crevicular fluid, whereas shotgun whole genome sequencing was performed for microbiome analysis in saliva, serum and plaque.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 12, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2020
CompletedFirst Submitted
Initial submission to the registry
November 4, 2024
CompletedFirst Posted
Study publicly available on registry
November 5, 2024
CompletedNovember 5, 2024
November 1, 2024
2 months
November 4, 2024
November 4, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Host proteomics profiles from saliva, serum and GCF
Concentrations
24 hours after clinical periodontal measurements
Microbial profiles from subgingival plaque and saliva
Linear discriminant analysis scores
24 hours after clinical periodontal measurements
Study Arms (1)
Periodontitis
These patients had at least two interdental sites (at two non-adjacent teeth) with interproximal CAL ≥5 mm, along with PD ≥6 mm and RBL extending to the mid-third of the root or beyond. CAL was not originated from endodontic lesions draining through the marginal periodontium, dental caries extending into the cervical areas of the teeth, trauma-related gingival recession or distal bone loss in 2nd molars owing to extractions of 3rd molars. They had ≤4 teeth lost due to periodontitis.
Interventions
Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.
The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.
5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.
GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.
Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.
Eligibility Criteria
A total of three systemically healthy and non-smoking patients with stage III, grade C peridontitis (3 males; age range 43 to 60 years) were consecutively enrolled from the population seeking periodontal treatment for the first time at the Department of Periodontology, School of Dentistry, Aydın Adnan Menderes University, Aydın, Turkey, between December 2019 to February 2020.
You may qualify if:
- No history of smoking
- At least 24 natural teeth (excluding 3rd molars)
You may not qualify if:
- Being diagnosed with diabetes mellitus, rheumatoid arthritis, cardiovascular system diseases, endocrine, immunologic, and mucocutaneous disorders
- Use of antibiotics, antihypertensives immunosuppressive, anti-inflammatory drugs and topical antiseptic solutions within the past 6 months
- Having periodontal treatment in the previous year
- Wearing removable partial dentures or orthodontic appliances
- Pregnant or nursing women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Aydın Adnan Menderes University, Faculty of Dentistry, Department of Periodontology
Aydin, 09100, Turkey (Türkiye)
Biospecimen
Saliva, serum, gingival crevicular fluid and subgingival plaque
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nagihan Bostanci
Karolinska Institutet
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assoc. Prof.
Study Record Dates
First Submitted
November 4, 2024
First Posted
November 5, 2024
Study Start
December 4, 2019
Primary Completion
February 12, 2020
Study Completion
May 15, 2020
Last Updated
November 5, 2024
Record last verified: 2024-11